The Alliance for Regenerative Medicine Announces Third Annual State of the Industry Briefing

– December 19, 2012

WASHINGTON, DC, December 18, 2012 – The Alliance for Regenerative Medicine (ARM), the international organization representing the interests of the regenerative medicine community, today announced that the third annual State of the Industry Briefing will take place on January 8, 2013 in San Francisco.

The session will include two panels comprised of leading experts in the field. The first panel will provide an in-depth analysis of recent developments in regenerative medicine, with speakers from leading companies and patient advocacy groups. The second panel will cover the outlook for the sector from the investor perspective, and will feature expert healthcare buy side and sell side analysts focused on regenerative medicine and other advanced therapies.

“This is a time of terrific activity and excitement in regenerative medicine,” said Geoff MacKay, President & Chief Executive Officer of Organogenesis Inc., and incoming Chairman of ARM. “The field has matured to the point where it is fostering new innovations, while also developing unique models needed to commercialize living technologies to reach patients. Additionally, as our healthcare system prepares for an aging population and an increasing prevalence of chronic diseases, regenerative medicine will play an increasingly important role in patient care. We look forward to exploring these issues in the State of the Industry Briefing.”

Confirmed speakers include incoming ARM Chairman and State of the Industry Briefing moderator, Geoff MacKay, President & CEO, Organogenesis, as well as ARM Vice Chair, Keith Murphy, President & CEO, Organovo, who will moderator the Analyst Outlook Panel.  Additional panelists include Chris Calhoun, CEO, Cytori Therapeutics; Jeffrey Jonas, President, Shire Regenerative Medicine; Jason Kolbert, Senior Biotechnology Analyst, Maxim Group; Robert Palay, CEO, Cellular Dynamics International; Susan Solomon, CEO, New York Stem Cell Foundation; Matthias Steger, Global Head Research & Technology Partnering, Roche Ltd.; Gil Van Bokkelen, Chairman & CEO, Athersys, Inc.

This event was developed by the Alliance for Regenerative Medicine (ARM), and will be held as part of the Biotech Showcase 2013 conference taking place at the Park 55 Wyndham in San Francisco from 8:00 a.m. to 10:00 a.m. These sessions are open to the public and do not require paid registration for the Biotech Showcase to attend.  Space is limited for these sessions and it is strongly recommended interested parties RSVP in advance. To learn more and to RSVP, please visit

The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, click here.

Media Contact: Michelle Linn Linnden Communications Phone: 508-362-3087